Specific gastric cancer population key to positive final NICE guidance on Roche's Herceptin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final guidance recommending Roche's anticancer Herceptin (trastuzumab) for some patients with metastatic gastric cancer. Defining a specific patient subgroup – patients who express high levels of HER2 – proved the key to winning a positive recommendation.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.